GlassScriptPhysician profile
Suzann Smith
NPI 1811220171
$3,541.63
in general payments reported to CMS, 2019-2025
29 companies · $682 in 2025
The $682 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.80 · 2022: $923 · 2023: $1,050 · 2024: $847 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $886.82 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $333.27 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $283.43 | 2021-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $236.57 | 2022-2023 | Verquvo, Steglatro |
| Janssen Pharmaceuticals, INC | $221.50 | 2023-2025 | Spravato |
| Axsome Therapeutics, INC. | $196.35 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $179.75 | 2021-2023 | Trulicity, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $130.26 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.02 | 2024-2025 | Caplyta |
| Dexcom, INC. | $101.17 | 2022-2023 | Dexcom G6 Transmitter |
| Alkermes, INC. | $98.09 | 2024-2025 | Aristada, Lybalvi |
| Indivior INC. | $94.78 | 2023-2025 | Sublocade |
| Lundbeck LLC | $94.70 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $89.10 | 2022-2024 | Farxiga |
| Vanda Pharmaceuticals INC. | $67.16 | 2025 | Hetlioz, Fanapt |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $59.73 | 2025 | Uzedy |
| Glaxosmithkline, LLC. | $50.20 | 2022-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $49.33 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.87 | 2022 | |
| Astellas Pharma US INC | $29.55 | 2023 | Myrbetriq, Veozah |
| Pfizer INC. | $27.92 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $26.88 | 2023 | |
| Biogen, INC. | $24.79 | 2025 | Zurzuvae |
| Amgen INC. | $23.03 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.79 | 2025 | Qelbree |
| Sanofi-Aventis U.S. LLC | $16.35 | 2022 | |
| Amarin Pharma, INC. | $14.21 | 2022 | |
| Almatica Pharma LLC | $13.55 | 2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzann Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.